Antifungal susceptibility of non-albicans Candida spp. isolated from raw milk and human blood in Alborz and Tehran provinces

Zahra Namvar¹, Abbas Akhavan Sepahy¹*, Robab Rafiei Tabatabaei¹, Sassan Rezaie²

¹Department of Microbiology, School of Biological Sciences, Islamic Azad University, North Tehran Branch, Tehran, Iran
²Department of Medical Mycology and Parasitology, Division of Molecular Biology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

ABSTRACT

Background and Objectives: Recent reports indicate high prevalence of fungal infections due to non-albicans Candida spp. which are present in various environments such as raw milk. The quality of milk for fungal normal flora was investigated in this study.

Materials and Methods: A total of 262 milk samples were collected directly from milk collection tanks in designated dairy farms and cultured in SDA media. By further analysis of grown yeasts, 69 non-albicans Candida strains were identified. Antifungal susceptibility of the isolated species, were evaluated against amphotericin B, itraconazole, fluconazole and fluocytosine. Fifty two non-albicans clinical samples isolated from human blood have been evaluated along.

Results: Antifungal susceptibility evaluation in non-albicans strains isolated from milk revealed Candida glabrata and Candida tropicalis to be 100% sensitive to fluocytosine and fluconazole. Candida krusei showed 94% and 80% sensitivity to fluocytosine and fluconazole respectively. Candida parapsilosis indicated 72.72% sensitivity to fluconazole.

Conclusion: Evaluation of non-albicans Candida species in raw milk and antifungal susceptibility patterns of these isolates-compare with non-albicans isolates from human blood, may help physicians to choose an appropriate medication for diseases needing long-term treatment, especially for diseases caused by local strains.

Keywords: Candida parapsilosis; Candida glabrata; Candida krusei; Candida tropicalis; Antifungal; Raw milk

INTRODUCTION

Fungi are eukaryotic microorganisms which can be present in different environments. Raw milk of livestock such as cows is considered; as a complete food source, and a proper environment for some fungi such as yeasts.

The secondary metabolites of fungi, such as mycotoxins, are generally of public health importance and have been studied excessively in milk. The prevalence of fungi in raw milk as well as the drug resistance of fungi associated with raw milk normal flora is worthy of consideration in terms of public health (1). Candida are small, thin-walled yeasts that propagate through budding. Candidiasis is an infection caused by different species of candida, especially C. albicans. In the last two decades, the frequency and severity of infections have increased dramatic-
ly following the widespread use of antibiotics, steroids and other immunosuppressive drugs. *Candida* species are found everywhere in human and animal coexistence. Numerous species cause candidiasis, in different parts of the body. Deep-systemic candidiasis involves blood or other internal organs are seen in people with weak or defective immune systems (2–4).

Recently, a high prevalence of nosocomial infections of yeast origin has been reported in which *C. albicans* is mainly implicated (80%) (5). However, non-albicans *Candida* spp. are the main opportunistic pathogens associated with comorbidity in patients with immunodeficiencies, cancers, and organ transplant recipients (6). The most important challenge in the facing infections caused by non-albicans *Candida* spp is their drug resistance to conventional antifungal drugs. These species, known as emerging pathogens, are the cause of uncontrolled nosocomial infections.

In this study, we investigated the presence of non-albicans *Candida* spp. in raw cow milk and evaluated their antifungal resistance profile compare to clinical isolates of non-albicans *Candida* spp. The results may bring us better knowledge about the yeast content in raw cow-milks and related antifungal resistance profile.

**MATERIALS AND METHODS**

**Sample preparation.** Sampling was carried out during the four seasons of spring, summer, autumn, and winter. A total of 262 milk samples were taken from 14 designated dairy farms located in Tehran and Alborz provinces. Using sterile Falcon tubes, about 10 ml of milk were taken from raw milk-collecting tanks in the mentioned farms and were transported to the laboratory for further processing.

**Isolation of strains.** Milk samples were cultured on Sabouraud dextrose agar (SDA) culture media containing penicillin and streptomycin and were incubated at 37°C for one week. Obtained yeast colonies were then examined using candida chrom-agar culture media and were primarily differentiated based on their colors. However, for complete identification and confirmation, a part of rDNA in the ITS region has been amplified for sequencing in all isolates. Briefly, high molecular weight DNA was extracted from the samples using the glass bead and phenol-chloroform method as described previously (7). Using specific nucleotide primers for ITS region; ITS1-S:3’TCC GTA GGT GAA CCT GCG G5’ and ITS4-AS:3’ TCC TCC GCT TAT TGA TAT GC5’, a part of 28S of rDNA was amplified in each isolate by PCR method as described previously (8). Nucleotide sequencing of the obtained amplicons were performed and the results were compared in gene data bank (NCBI, NIH) for confirmation of identity.

**MIC analysis.** Antifungal susceptibility testing was performed for obtained non albicans isolates including: *C. parapsilosis*, *C. krusei*, *C. glabrata* and *C. tropicalis* against amphotericin B, itraconazole, fluconazole and flucytosine. Minimum inhibitory concentration (MIC) for the growth of these yeasts was determined using clinical and laboratory standard protocol (CLSI, M27-A3) and microdilution method (9). Fungi were grown on SDA culture media at 35°C for 48 h. About 1mm of grown yeast colonies were dissolved in 7 ml of sterile distilled water. The cell density of the resultant suspension was adjusted at a wavelength of 530 nm by adding enough sterile water to obtain 75-77% transmittance which indicated cell density as 1-5 × 10^6 cells/ml. The initial suspension was then diluted with RPMI 1640 broth medium to achieve a working suspension with cell density of 0.5-2.5 × 10^3 cells/ml.

In this study, *C. parapsilosis* ATCC 22019 was used for quality control.

**RESULTS**

**Identification of samples.** Different types of yeasts were isolated and identified from 66% of 262 milk samples. Due to their similarity to common pathogens in clinical samplings, the antifungal resistance test was performed on 4 species including; *C. tropicalis*, *C. parapsilosis*, *C. glabrata*, *C. krusei*. Identified *C. krusei* and *C. parapsilosis* samples were isolated at all seasons, while *C. tropicalis* was not isolated in winter and *C. glabrata* was isolated only in the winter.

At whole 69 non-albicans candida strains were isolated in 262 collected milk samples. Based on ITS sequencing results, 2 cases (0.76%) were identified as *C. glabrata*, 6 cases (2.29%) as *C. tropicalis*, 11 cases (4.19%) as *C. parapsilosis* and 50 cases (19.8%) as *C. krusei*. 

http://ijm.tums.ac.ir
MIC analysis. The results of MIC analysis for raw milk samples showed the MIC<sub>50</sub> value of fluconazole as 0.031, 0.125, 0.062 and 1 for C. glabrata, C. parapsilosis, C. tropicalis and C. krusei strains respectively. MIC analysis for human blood samples showed that the MIC<sub>50</sub> value of flucytosine was 0.062, 0.125, 0.062 and 1 for C. glabrata, C. parapsilosis, C. tropicalis and C. krusei strains. The results of MIC analysis showed that MIC<sub>50</sub> of flucytosine was more effective on all tested specimens except for C. krusei. For C. krusei strains, itraconazole with MIC<sub>50</sub> = 0.5 was more effective than flucytosine with MIC<sub>50</sub> = 1. Besides, the drug of choice for C. glabrata, C. parapsilosis and C. tropicalis strains were also determined to be itraconazole with MIC<sub>50</sub> = 1.125 (Table 1).

Table 1 shows in vitro susceptibility of Non-albicans Candida yeast from raw milk tested against four antifungal. In the study, all isolates of C. glabrata and C. tropicalis as well as 94% of C. krusei isolates were sensitive to flucytosine. The sensitivity of C. glabrata, C. tropicalis, C. parapsilosis and C. krusei strains to fluconazole were 100%, 100%, 72.72% and 80% respectively. This finding showed the high effect of this antimicrobial medication on non-albicans Candida spp. The frequency of sensitive and resistant strains of non-albicans Candida isolated in raw cow-milk is shown in Table 2.

In this study, a comparison was done regarding the susceptibility testing results between the isolated cow milk and clinically isolated non-albicans Candida strains. It was shown that clinical non-albicans Candida isolates were also sensitive (100%) to fluconazole. MICs of antifungal medications and the frequency of resistant and sensitive clinical non-albicans Candida isolates used in this study have been shown in Tables 3 and 4, respectively.

MIC ranges of fluconazole, itraconazole, amphotericin B, and flucytosine against the non-albicans Candida spp. in this study were 0-64, 0.015-16, 0.0125-16 and 0.031-1 μg/mL, respectively, while MIC ranges of fluconazole, itraconazole, amphotericin B, and flucytosine against the clinically isolated non-albicans Candida spp. were 0.125-64, 0.015-16, 0.06-4 and 0.031-1 μg/mL, respectively.

**DISCUSSION**

Since milk is mentioned as a complete food source in all age groups particularly in children and in elderly, its quality and drug resistance rate of its microorganisms are of great importance because they may be substituted for the body natural flora.

In this study, from a total of 69 non-albicans Candida strains isolated from raw milk, 2 isolates (0.76%)...
Table 2. Interpretation of the sensitivity results of *Candida* non-albicans isolates from raw milk evaluated based on CL-SI-M27-A3 proposed breakpoints or ECV.

| Species (Number) | Antifungal Drugs | Sensitive N (%) | Dose-Dependent N (%) | Resistant N (%) |
|------------------|------------------|------------------|----------------------|-----------------|
| *C. glabrata* (n=2) | fluconazole | 2 (100) | - | - |
| | itraconazole | - | 1 (50) | 1 (50) |
| | flucytosine | 2 (100) | - | - |
| | amphotericin B | 1 (50) | - | 1 (50) |
| *C. tropicalis* (n=6) | fluconazole | 6 (100) | - | - |
| | itraconazole | 2 (33.33) | 4 (66.66) | - |
| | flucytosine | 6 (100) | - | - |
| | amphotericin B | 3 (50) | - | 3 (50) |
| *C. parapsilosis* (n=11) | fluconazole | 8 (72.72) | 1 (9.09) | 2 (18.18) |
| | itraconazole | 4 (36.36) | 2 (18.18) | 5 (45.45) |
| | flucytosine | 11 (100) | - | - |
| | amphotericin B | 6 (54.54) | - | 5 (45.45) |
| *C. krusei* (n=50) | fluconazole | 40 (80) | 4 (8) | 6 (12) |
| | itraconazole | 14 (28) | 20 (40) | 16 (32) |
| | flucytosine | 47 (94) | 3 (6) Intermediate | - |
| | amphotericin B | 24 (48) | - | 26 (52) |

Table 3. Susceptibility of non-albicans *Candida* from human tested against four antifungal.

| Isolates (Number) | Antifungal Drugs | MIC Range | MIC (μg/mL) |
|-------------------|------------------|-----------|-------------|
| | | MIC\textsubscript{50} | MIC\textsubscript{90} | GM |
| *C. glabrata* (n=24) | fluconazole | 0.25-32 | 16 | 64 | 9.281035 |
| | itraconazole | 0.062-2 | 1 | 2 | 0.672757 |
| | amphotericin B | 0.25-1 | 1 | 1 | 0.707106 |
| | flucytosine | 0.5-0.031 | 0.062 | 0.5 | 0.085471 |
| *C. parapsilosis* (n=17) | fluconazole | 0.125-64 | 0.5 | 64 | 0.567889 |
| | itraconazole | 0.015-2 | 0.125 | 0.5 | 0.143093 |
| | amphotericin B | 0.06-1 | 0.5 | 1 | 0.431183 |
| | flucytosine | 0.5-0.031 | 0.125 | 0.5 | 0.111015 |
| *C. tropicalis* (n=10) | fluconazole | 4-64 | 16 | 64 | 24.870501 |
| | itraconazole | 1-16 | 8 | 16 | 7.511447 |
| | amphotericin B | 0.5-1 | 1 | 1 | 0.777203 |
| | flucytosine | 0.5-0.031 | 0.062 | 0.4625 | 0.071391 |
| *C. krusei* (n=1) | fluconazole | 0.5-8 | 2 | - | 2.677899 |
| | itraconazole | 0.25-2 | 0.5 | - | 0.629960 |
| | amphotericin B | 0.25-4 | 1 | - | 1.122462 |
| | flucytosine | 1 | 1 | - | 1 |

were identified as *C. glabrata*; both of which were sensitive to flucytosine and fluconazole. One of these two isolates was resistant to itraconazole and sensitive to amphotericin B, and the other one was dose-dependent to itraconazole and resistant to amphotericin B. Besides, 6 isolates (2.29%) were identified as *C. tropicalis*; all of which were sensitive to flucytosine and fluconazole. Of these, 2 cases were sensitive and 4 cases were dose-dependent to itraconazole. Among 6 isolates of *C. tropicalis*, 3 were sensitive and 3 were resistant to amphotericin B.
**Table 4. Interpretation of the sensitivity results of non-albicans Candida isolates from human evaluated based on CLSI-M27-A3 proposed breakpoints or ECV**

| Species (Number) | Antifungal Drugs | Sensitive N (%) | Dose-Dependent N (%) | Resistant N (%) |
|------------------|------------------|-----------------|----------------------|----------------|
| C. glabrata (n=24) | fluconazole      | 15 (62.5)       | 9 (37.5)             |                |
|                  | itraconazole     | 1 (4.2)         | 8 (33.3)             | 15 (62.5)      |
|                  | amphotericin B   | 24 (100)        | -                    | -              |
|                  | flucytosine      | 24 (100)        | -                    | -              |
| C. parapsilosis (n=17) | fluconazole  | 16 (94.1)       | -                    | 1 (5.9)        |
|                  | itraconazole     | 10 (58.8)       | 6 (35.3)             | 1 (5.9)        |
|                  | amphotericin B   | 17 (100)        | -                    | -              |
|                  | flucytosine      | 24 (100)        | -                    | -              |
| C. tropicalis (n=10) | fluconazole    | -               | 1 (10)               | 9 (90)         |
|                  | itraconazole     | -               | -                    | 10 (100)       |
|                  | amphotericin B   | 10 (100)        | -                    | -              |
|                  | flucytosine      | 24 (100)        | -                    | -              |
| C. krusei (n=1) | fluconazole      | 1 (100)         | -                    | -              |
|                  | itraconazole     | -               | -                    | 1 (100)        |
|                  | amphotericin B   | 1 (100)         | -                    | -              |
|                  | flucytosine      | 1 (100)         | -                    | -              |

_C. tropicalis_ species is considered as one of the common causes of disease in patients hospitalized in urinary and blood infections ward. Besides, _C. tropicalis_ has become resistant to amphotericin B due to the long-term treatment by this antibiotic (10). According to recent studies, _C. tropicalis_ use biofilm formation as a pathogenic agent, which may also be the cause of increased resistance to antifungal drugs (10).

In this study, 11 isolates (4.19%) were identified as _C. parapsilosis_; all of which were sensitive to flucytosine and fluconazole, except for 3 cases that were not sensitive to fluconazole. One of these 3 cases was dose-dependent, and the other two were resistant to fluconazole. In addition, among the 11 _C. parapsilosis_ strains, 5 cases were resistant, 2 cases were dose-dependent, and the rest were sensitive to itraconazole. Regarding amphotericin B, 6 cases were sensitive, and 5 cases were resistant.

From the total of 69 non-albicans _Candida_ strains, 50 (19.8%) were identified as _C. krusei_; all of which were sensitive to flucytosine, except for 3 cases which were reported as intermediate. Among the 50 isolates of _C. krusei_, 6 were resistant, 4 were dose-dependent, and 40 were sensitive to fluconazole. Also, 16, 20 and 14 isolates were resistant, dose-dependent, and sensitive to itraconazole respectively. Regarding amphotericin B, 26 isolates were resistant, and 24 isolates were reported as sensitive.

The most common cause of nosocomial infections among the _Candida_ species is _C. albicans_, accounting for 80% of nosocomial infections, while _C. glabrata_, _C. parapsilosis_ and _C. tropicalis_ account for 50, 50 and 10-25% of these infections. On the other hand, the presence of factors causing drug resistance in these fungi has caused most studies to be done on these microorganisms (5). Non-albicans _Candida_ resistance to azoles antifungal agents has made the treatment of infections caused by these fungi to be difficult; therefore, the high prevalence of infections with these yeasts is a serious challenge (11-13).

Recent studies have shown that fungi isolated from livestock were azoles resistant, suggesting that they were independent of the host type. Resistant strains can also live in healthy individuals as a reservoir of resistant strains (12). It is worth noting that increased fungal infections due to the difficulty in diagnosing fungal pathogenic agents and their resistance to commercial antifungal medications have led to an increase in mortality and morbidity rate, especially in patients with immunodeficiency or cancer (14). Today, fungal species and genera which are less sensitive or resistant to antifungal agents are considered as the main causes of invasive infections in patients.
with immunodeficiency and are more under consideration (15).

The prevalence of these pathogenic agents sometimes increases the resistance to antifungal medications in theses fungi, leading to an increase in drug use, including azoles. Therefore, it is necessary to specify the MIC value of antifungal medications in the laboratory before starting the treatment (5, 16, 17).

There were similarities and differences between the results of the present study, examining non-albicans Candida spp. isolated from livestock, and the results of other studies, examining clinical samples. MIC values obtained in this study for C. glabrata, C. parapsilosis and C. tropicalis isolates were not consistent with MIC results of clinical study of Baghdadi et al. (2016). The MIC of amphotericin B against the C. krusei isolates was consistent with the MIC results of Baghdadi’s study, but no other MIC was consistent (7). This inconsistency was due to the higher sensitivity of milk-isolated strains to the azoles. These findings can be attributed to the non-use of antifungal medications in livestock and less exposure of these microorganisms to antifungal drugs. Today, the presence of some factors have caused various antifungal drugs to be identified, including the increase in fungal infections, changes in various fungi epidemiology, fungi resistance to antifungal drugs, and new toxins production by them (18). Azoles with MIC_{≥} to MIC_{=8} are commonly used for the treatment of infections caused by yeasts (19).

There were similarities and differences between the results of present study and those of Mendes et al. (2018) study which conducted on antimicrobial susceptibility of fungi strains isolated from clinical samples, wild animals, and cow’s mastitis. Mendes et al. (2018), indicated that among the non-albicans Candida spp. used in the present study. In their study, only C. parapsilosis was common and the rate of sensitive isolates to amphotericin B was higher than those reported in the present study, but their results for flucytosine, and fluconazole are similar (5).

The specimens identified in this study were in common with those of Du et al. (2018), however, different results were obtained. Du et al. (2018) showed that the C. krusei samples were all resistant to fluconazole, flucytosine and itraconazole, whereas our study samples were 100% sensitive to phylocytosine. Also, the samples of the C. parapsilosis study Du et al. (2018) were resistant to phylocytosine but sensitive to fluconazole, whereas our samples were 100% sensitive to phylocytosine (20). Noteworthy is the type of population surveyed by Mendes and Du, both studies were conducted on cows’ mastitis, while the present study examined the milk of healthy cows; none of which used medication for treatment.

In a study by Perez et al. (2016) conducted on fungi isolated from birds and ruminants, all of the surveyed Candida species were similar to those of the present study, except for C. glabrata. They indicated that none of the fungi were resistant to amphotericin B and azole. However, in their research, the type of ruminants was unclear (12).

In the present study, interesting results were obtained by comparing the clinical and cow raw milk isolated non-albicans Candida strains. It was found that flucytosine was quite effective on both groups of isolates, and the effect of amphotericin B and fluconazole on C. parapsilosis was almost the same in both groups. In the case of C. krusei, the results of four antibiotics were more similar to each other, which can be attributed to the inherent resistance of this fungus. Since flucytosine has been less used for livestock; therefore, the sensitivity of non-albicans Candida spp. to which was reported as 100% in this study.

ACKNOWLEDGEMENTS

We thank our colleagues at Medical Mycology Laboratory, School of Public Health, Tehran University of Medical Sciences.

REFERENCES

1. Neviani E, Bottari B, Lazzi C, Gatti M. New developments in the study of the microbiota of raw-milk, long-ripened cheeses by molecular methods: the case of Grana Padano and Parmigiano Reggiano. Front Microbiol 2013;4:36.
2. Reiss E, Tanaka K, Bruker G, Chazalet V, Coleman D, Debeaupuis J, et al. Molecular diagnosis and epidemiology of fungal infections. Med Mycol 1998;36 Suppl 1:249-257.
3. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-1554.
4. Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med 2015: 373: 1445-1456.
5. Mendes J, Gonçalves C, Ferreira G, Esteves I, Freitas...
2. C, Villarreal I, et al. Antifungal susceptibility profile of different yeasts isolates from wild animals, cow’s milk with subclinical mastitis and hospital environment. *Braz J Biol* 2018;78:68-75.

6. de Aguiar Cordeiro R, Pereira de Alencar L, Nogueira Brilhante RS, de Souza Collares Maia Castelo-Branco D, Cordeiro Teixeira CE, de Brito Macedo R, et al. Antifungal susceptibility of emerging opportunistic yeasts and yeast-like fungi from Rhea americana. *Can J Microbiol* 2013;59:577-580.

7. Baghdadi E, Khodavaisy S, Rezaie S, Abolghasem S, Kiasat N, Salehi Z, et al. Antifungal susceptibility patterns of *Candida* species recovered from endotracheal tube in an intensive care unit. *Adv Med* 2016;2016:9242031.

8. Mohammadi R, Mirhendi H, Rezaei-Matehkolaee A, Ghahri M, Shidfar MR, Jalalizand N, et al. Molecular identification and distribution profile of *Candida* species isolated from Iranian patients. *Med Mycol* 2013;51:657-663.

9. Borghi E, Iatta R, Scioti R, Biassoni C, Cuna T, Montagna MT, et al. Comparative evaluation of the Vitek 2 yeast susceptibility test and CLSI broth microdilution reference method for testing antifungal susceptibility of invasive fungal isolates in Italy: the GISIA3 study. *J Clin Microbiol* 2010;48:3153-3157.

10. Fernandes T, Silva S, Henriques M. *Candida tropicalis* biofilm's matrix—involvement on its resistance to amphotericin B. *Diagn Microbiol Infect Dis* 2015;83:165-169.

11. Bruder-Nascimento A, Camargo CH, Mondelli AL, Sugizaki MF, Sadatsume T, Bagagli E. *Candida* species biofilm and *Candida* albicans ALS3 polymorphisms in clinical isolates. *Braz J Microbiol* 2014;45:1371-1377.

12. Álvarez-Pérez S, García ME, Peláez T, Martínez-Nevalvo E, Blanco JL. Antifungal susceptibility testing of ascomycetous yeasts isolated from animals. *Antimicrob Agents Chemother* 2016; 60: 5026-5028.

13. Silva S, Henriques M, Martins A, Oliveira R, Williams D, Azeredo J. Biofilms of non- *Candida* albicans *Candida* species: quantification, structure and matrix composition. *Med Mycol* 2009;47:681-689.

14. Chagas-Neto TC, Chaves GM, Melo AS, Colombo AL. Bloodstream infections due to *Trichosporon* spp.: species distribution, *Trichosporon* asahii genotypes determined on the basis of ribosomal DNA intergenic spacer 1 sequencing, and antifungal susceptibility testing. *J Clin Microbiol* 2009;47:1074-1081.

15. Haziroglan G, Canton E, Sahin S, Arikan-Akdağlı S. Head-to-head comparison of inhibitory and cidal activities of fluconazole, itraconazole, voriconazole, posaconazole and isavuconazole against clinical isolates of *Trichosporon* asahii determined by three methods: MIC, minimum fungicidal concentration and time-kill curves. *Antimicrob Agents Chemother* 2013;57:4841-4847.

16. Kludze-Forson M, Eschenauer GA, Kubin CJ, Del-la-Latta P, Lam SW. The impact of delaying the initiation of appropriate antifungal treatment for *Candida* bloodstream infection. *Med Mycol* 2010;48:436-439.

17. Smith KD, Achan B, Hullsiekh KH, McDonald TR, Okagaki LH, Alhadab AA, et al. Increased antifungal drug resistance in clinical isolates of *Cryptococcus* neoformans in Uganda. *Antimicrob Agents Chemother* 2015;59:7197-204.

18. Milici ME, Maida CM, Sprechini E, Ravazzolo B, Oliveri S, Scalise G, et al. Comparison between disk diffusion and microdilution methods for determining susceptibility of clinical fungal isolates to caspofungin. *J Clin Microbiol* 2007;45:3529-3533.

19. Thompson III GR, Wiederhold NP, Sutton DA, Fothergill A, Patterson TF. *In vitro* activity of isavuconazole against *Trichosporon*, *Rhodotorula*, *Geotrichum*, *Sacccharomyces* and *Pichia* species. *J Antimicrob Chemother* 2009;64:79-83.

20. Du J, Wang X, Luo H, Wang Y, Liu X, Zhou X. Epidemiological investigation of non-albicans *Candida* species recovered from mycotic mastitis of cows in Yinchuan, Ningxia of China. *BMC Vet Res* 2018;14:251.